Skip to main content
S&P 5007,591.70-0.58%DOW52,064.10-0.60%NASDAQ26,081.72-0.65%BTC$77,006.00-1.13%ETH$2,464.11-0.04%GOLD$4,387.10-0.46%OIL$99.06-3.34%
Smart Investors Daily
FE

NASDAQ · FEMY

Femasys Inc.

Healthcare · Medical - Instruments & Supplies

$2.74

Down-$0.09 (-3.18%)

Updated Sep 11, 2026, 10:55 AM

SID Score

5.0/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
25.19M
P/E ratio
-1.77
Dividend yield
0.00%
52-week range
$0.33 – $7.60
Volume
35.53K
Avg. volume
8.09M

Price performance

FEMY price history

1M range · 0 trading sessions · Daily adjusted prices

FEMY does not have enough price history for the selected period.

Data unavailable

Market data is busy. Please try again shortly.

Latest FEMY news

The latest Smart Investors Daily articles mentioning FEMY.

Stock researchCompany · Overview

FEMY research

Overview

Company profile and research snapshot.

Company profile

Femasys Inc is a biomedical company focused on transforming women's healthcare by developing solutions and advancements providing clinical impact to address severely underserved areas. The company's mission is to provide women with minimally invasive, non-surgical product technologies, accessible in the office, improving patient care and overall health economics. Its product portfolio includes FemaSeed Intratubal Insemination, an infertility treatment; FemVue, a companion diagnostic for fallopian tube assessment via ultrasound; FemBloc, a clinical product candidate being developed as a permanent birth control; FemCerv, a tissue sampler for cervical cancer diagnosis; and FemCath and FemChec. Geographically, it derives key revenue from the United States and rest from international markets.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
FEMY recent ratings
DateFirmRatingTarget
Aug 18, 2026Lake StreetBuy—
Aug 14, 2026Maxim GroupBuy—
Mar 3, 2026Lake StreetBuy—
Nov 20, 2025Laidlaw & Co.Buy—
Aug 11, 2025HC Wainwright & Co.Buy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Aug 26, 2026

Femasys Partners with UNC Health to Introduce Its FemaSeed® Fertility Portfolio Across Statewide OB/GYN Care Locations

-- For the first time, OB/GYNs within the UNC Health system will be able to offer women FemVue® fertility evaluation and FemaSeed as a first-line treatment option -- ATLANTA, Aug. 26, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator developing transformative fertility and non-surgical permanent birth control solutions designed to improve the standard of care, expand access, and reduce costs for women worldwide, announced today a partnership with UNC Health to

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By